June 2010
Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p10
The article offers news briefs related to medicine in the U.S. Results from the TRINITY study proved that the triple therapy of olmesrtan medoxomil, amlodipine besylate, and hydrochlorothiazide (HCTZ) showed greater mean reductions in blood pressure at 12 weeks compared with dual therapy. Bayer Schering Pharma AG conducted a Phase III trial of regorafenib, an oral multi-kinase inhibitor with a kinase inhibitor profile targeting angiogenic, stromal, and oncogenic receptor tyrosine kinase.


Related Articles

  • Alemtuzumab In Phase III Testing Against Rebif In MS.  // BioWorld Today;9/27/2007, Vol. 18 Issue 188, p3 

    The article focuses on the first of two Phase III studies by Genzyme Corp. and Bayer Schering Pharma AG comparing the effects of alemtuzumab and Rebif on 525 patients with relapsing-remitting multiple sclerosis. Through the test, Genzyme and Bayer hope to confirm results from a previous Phase II...

  • Bayer Schering/Onyx: Nexavar suffers setback in lung cancer.  // PharmaWatch: Monthly Review;Apr2008, Vol. 7 Issue 4, p7 

    The article reports that the Phase III trial of Nevaxar for non-small-cell lung cancer from Bayer Schering Pharma AG and Onyx Pharmaceuticals Inc. has been stopped. This move results after a planned interim analysis showed that the study will not meet its primary endpoint of an improvement in...

  • Src Inhibitors as Potential Therapeutic Agents for Human Cancers. Trevino, Jose G.; Summy, Justin M.; Gallick, Gary E. // Mini Reviews in Medicinal Chemistry;Jun2006, Vol. 6 Issue 6, p681 

    Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an...

  • The Role of SRC in Capacitation.  // Fertility Weekly;9/22/2008, p2 

    The article discusses the results of the study by Australian researches on the role of protein kinase A (PKA)-activated tyrosine kinase pp60 (SRC), a protein domain. SRC increases the tyrosine phosphorylation that correlates with human sperm capacity, according to the study. The study shows...

  • NICE recommends all patients admitted to hospital are risk assessed for VTE.  // Operating Theatre Journal;Feb2010, Issue 233, p3 

    The article announces the launching of Bayer Schering Pharma AG with its implementation toolkit for the prevention of Venous Thromboembolism (VTE) in Great Britain.

  • Treatment Guidelines.  // Current Medical Literature: Kidney Cancer;Sep2009, Vol. 1 Issue 3, p80 

    The article focuses on the efficiency on the use of clinical data to support the development for advanced renal cell carcinoma (RCC) as found in the report in Great Britain. The report guideline states on the absence of evidence to support on the use of medical therapy as an adjuvant therapy...

  • Healthcare: Ethical Bayer Australia.  // Media: Asia's Media & Marketing Newspaper;11/19/2009, p33 

    The article reports on the use of public relations (PR) by Bayer Schering Pharma AG (BSP) as the main marketing platform to launch its oral contraceptives in Australia in 2009.

  • BiTE Advances to Preclinical Studies.  // Drug Discovery & Development;Nov2010, Vol. 13 Issue 9, p23 

    The article reports on the plans of Micromet Inc. to advance its BiTE antibody MT112/BAY2010112 into formal preclinical development in collaboration with Bayer Schering Pharma AG.

  • New progestins eyed for contraception in U.S.  // Contraceptive Technology Update;Aug2009, Vol. 30 Issue 8, p89 

    The article reports on the clinical trials conducted by biopharmaceutical company Bayer Schering Pharma AG on the use of contraceptive progestins using ethinyl estradiol and gestodene among women in the U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics